Daily Cardiology Research Analysis
Analyzed 205 papers and selected 3 impactful papers.
Summary
Three impactful advances span mechanistic discovery, diagnostic innovation, and guideline implementation. A translational study identifies the cGMP–PKG–ULK1 autophagy axis as a modulator of aortic valve calcification and positions vericiguat as a potential therapy. A multicenter validation confirms a novel nonhyperemic pressure ratio (cRR) using a pressure microcatheter with high diagnostic accuracy, while the 2026 ACC/AHA multisociety dyslipidemia guideline updates evaluation and management across LDL-C, triglycerides, and lipoprotein(a).
Research Themes
- Mechanistic targeting of calcific aortic valve disease via cGMP–PKG–ULK1 autophagy
- Catheter-based physiology without hyperemia: validation of cRR using pressure microcatheters
- Updated multisociety guidance for dyslipidemia including lipoprotein(a) and hypertriglyceridemia
Selected Articles
1. Cyclic guanosine monophosphate-protein kinase G signaling attenuates aortic valve calcification through ULK1-mediated autophagy.
The study demonstrates that suppressed cGMP–PKG signaling in human calcified valves drives osteogenic remodeling, while genetic PKGI deficiency aggravates CAVD in mice. Pharmacologic activation (vericiguat > BNP ≈ sildenafil) reduces VIC calcification, preserves mitochondrial function, and inhibits inflammation by enhancing ULK1 (Ser556)-mediated autophagic flux, attenuating disease in ex vivo and in vivo models.
Impact: This work elucidates a previously undefined mechanistic axis (PKG–ULK1–autophagy) linking mitochondrial homeostasis and calcification in CAVD and nominates vericiguat as a repurposable therapy. It bridges human pathology, genetics, and pharmacology, offering a tangible therapeutic hypothesis for a disease lacking medical therapy.
Clinical Implications: If validated clinically, sGC stimulation to boost PKG–ULK1 autophagy could slow valve calcification, complementing or delaying TAVR/SAVR. Serum cGMP and imaging may serve as pharmacodynamic biomarkers to select and monitor patients.
Key Findings
- Human CAVD valves showed suppressed cGMP–PKG signaling; serum cGMP inversely correlated with calcification severity.
- PKGI haploinsufficiency aggravated valve calcification and hemodynamic burden in murine CAVD models.
- Pharmacologic activation (vericiguat, BNP, sildenafil) attenuated VIC osteogenic differentiation and leaflet calcification; vericiguat had the strongest effect.
- PKGI phosphorylated ULK1 at Ser556, enhancing autophagic flux, preserving mitochondrial function, and reducing oxidative stress/inflammation.
Methodological Strengths
- Translational breadth: human tissue correlations, genetic mouse models, ex vivo valve culture, and in vitro human VIC assays.
- Mechanistic dissection linking PKG to ULK1 phosphorylation and autophagy with functional mitochondrial readouts.
Limitations
- Predominantly preclinical; clinical efficacy and dosing of sGC stimulation for CAVD remain untested.
- Potential off-target and hemodynamic effects of agents (e.g., vericiguat) in elderly calcific valve populations require careful evaluation.
Future Directions: Early-phase trials testing sGC stimulators (e.g., vericiguat) in CAVD with imaging endpoints, biomarker-guided selection (cGMP), and mechanistic substudy of ULK1-autophagy in human valve tissue.
Calcific aortic valve disease (CAVD) is a prevalent age-related valvulopathy characterized by high morbidity and mortality. CAVD pathogenesis involves maladaptive differentiation of valvular interstitial cells (VICs) into profibrotic and osteogenic phenotypes, yet the underlying mechanisms remain unclear. Emerging evidence implicates cyclic guanosine monophosphate (cGMP)-protein kinase G (PKG) signaling in mitigating calcification. However, its molecular actions are poorly defined. Here, we found that the cGMP-PKG signaling
2. Clinical Validation of a Novel Pressure Microcatheter-Based Nonhyperemic Pressure Ratio (SUPREME II Study).
In a multicenter prospective validation, cRR measured by pressure microcatheter accurately identified functionally significant lesions using a 0.89 cutoff (AUC 0.92; sensitivity 87%; specificity 80%). The protocol randomized device order and demonstrated high feasibility, supporting cRR as a practical, nonhyperemic alternative that can reduce vasodilator use via a hybrid strategy.
Impact: Introduces and validates a nonhyperemic index deployable through pressure microcatheters, enabling physiologic assessment when pressure wires or hyperemia are impractical or undesirable. This can streamline workflow and broaden physiologic guidance in PCI.
Clinical Implications: Adoption of cRR could reduce vasodilator use, shorten procedural time, and extend physiology to complex anatomies or microcatheter-favored scenarios (e.g., tortuous vessels, ostial lesions). Hybrid cRR–FFR strategies may optimize decision-making.
Key Findings
- Prospective multicenter validation (466 patients, 483 vessels, 11 centers) established a cRR cutoff of 0.89 with 82.8% accuracy.
- Sensitivity and specificity versus FFR reference were 87.0% and 80.1%, with AUC 0.92.
- Randomized order of PMC and wire measurements under resting and hyperemic conditions demonstrated feasibility and methodological robustness.
- Hybrid strategies defined a cRR “gray zone” and enabled diagnosis without vasodilators in a substantial subset.
Methodological Strengths
- Prospective multicenter design with randomized device order minimizes sequence and center biases.
- Predefined reference standard and cut-point derivation with comprehensive operating characteristics.
Limitations
- Primary reference standard used PMC-based FFR ≤0.80; generalizability to pressure-wire FFR as sole reference warrants confirmation.
- Study focused on diagnostic performance; clinical outcome impact and cost-effectiveness were not assessed.
Future Directions: Outcome-driven trials comparing cRR-guided versus standard physiology-guided PCI, assessment in specific lesion subsets, and health-economic analyses to support adoption.
BACKGROUND: The constant resistance ratio (cRR) is a novel nonhyperemic pressure ratio based on piezoresistive pressure microcatheter (PMC) measurements. With repeated measurements in randomized order of PMC and pressure wire techniques, this study aimed primarily to validate the diagnostic performance of cRR compared with fractional flow reserve (FFR) in coronary lesions of 30% to 90% diameter stenosis. METHODS: SUPREME II (Sensor-Equipped Ultrathin Pressure Microcatheter Versus Pressure Wire for Physiological Measurements) was a multicenter, prospective study that included 466 patients (483 vessels) from 11 centers. All target vessels were assessed using both pressure wire and PMC separately in randomized order under resting and hyperemic conditions. The primary end point was the diagnostic accuracy of the cRR using a PMC-based FFR of ≤0.80 as the reference standard. Secondary end points included the cRR "gray zone" of the cRR-FFR hybrid strategy and the proportion of patients in whom diagnosed was achieved without vasodilator use. RESULTS: The optimal cRR cutoff was 0.89, which correctly classified 82.8% of the patients, with a sensitivity and specificity of 87.0% and 80.1%, respectively, and achieved an area under the curve of 0.92 with FFR CONCLUSIONS: In coronary stenosis of 30% to 90% diameter stenosis, cRR measurements were highly feasible. The diagnostic accuracy of cRR with FFR REGISTRATION: URL: https://clinicaltrials.gov/study/NCT05417763; Unique Identifier: NCT05417763.
3. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
This multisociety guideline replaces the 2018 cholesterol document and synthesizes contemporary evidence (search through Dec 2024) to update evaluation, management, and monitoring of dyslipidemias, including hypertriglyceridemia and elevated lipoprotein(a). It provides a unified framework for clinical decision-making across prevention and treatment.
Impact: Practice-defining guidance from ACC/AHA and partners realigns lipid care with contemporary evidence, expanding scope beyond LDL-C to triglycerides and lipoprotein(a), and standardizing monitoring strategies.
Clinical Implications: Clinicians should reassess patient panels for triglyceride-driven risk and lipoprotein(a), align therapy selection and monitoring to updated guidance, and integrate recommendations into prevention, secondary prevention, and familial dyslipidemia care pathways.
Key Findings
- Retires and replaces the 2018 AHA/ACC cholesterol guideline with a comprehensive dyslipidemia management framework.
- Evidence synthesis conducted via focused searches (Oct–Dec 2024) across major databases and agencies.
- Scope explicitly includes evaluation, management, and monitoring of high cholesterol, hypertriglyceridemia, and elevated lipoprotein(a).
Methodological Strengths
- Multisociety development with comprehensive evidence synthesis across major databases.
- Clear scope spanning evaluation, management, and monitoring across dyslipidemia phenotypes.
Limitations
- Abstract does not detail specific recommendations or strength/grade; full guideline required for granular guidance.
- Search limited to English-language publications and through December 2024, potentially excluding emergent data.
Future Directions: Implementation science to evaluate uptake and outcomes; prospective studies to refine lipoprotein(a) thresholds/therapies and triglyceride management strategies.
AIM: The "2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia" retires and replaces the "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol." METHODS: A comprehensive literature search was conducted from October 2024 to December 2024 to identify clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. STRUCTURE: The focus of this clinical practice guideline is to address the evaluation, management, and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a).